<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric Padron, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sandeep Gurbuxani, MBBS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 02, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H37528739">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic myelomonocytic leukemia (CMML) is a hybrid hematologic malignancy with clinical and pathological features of both myeloproliferative neoplasms (MPN) and myelodysplastic neoplasms/syndromes (MDS). CMML is characterized by peripheral blood monocytosis and bone marrow dysplasia, often accompanied by splenomegaly, constitutional symptoms, and/or cytopenias. CMML is a clinically and genetically distinct entity. The clinical features of CMML are heterogeneous, but it can be among the most aggressive of the chronic leukemias, with a propensity for progression to acute myeloid leukemia (AML).
        </p>
        <p>
         The epidemiology, evaluation, and diagnosis of CMML are reviewed here.
        </p>
        <p>
         Management and prognosis of CMML are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128330.html" rel="external">
          "Chronic myelomonocytic leukemia: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37528745">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of CMML is not well understood. There is no single disease-defining chromosomal abnormality or mutation, but some genetic abnormalities may enhance hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and monocytopoiesis.
        </p>
        <p>
         The most common cytogenetic abnormalities in CMML are trisomy 8 and various abnormalities of chromosome 7 [
         <a href="#rid1">
          1
         </a>
         ]. Mutations in epigenetic modifiers and regulators of mRNA splicing occur in up to 80 percent of cases of CMML [
         <a href="#rid2">
          2
         </a>
         ]. The most common mutations involve epigenetic modifiers (eg,
         <em>
          TET2
         </em>
         ,
         <em>
          ASXL1
         </em>
         ,
         <em>
          EZH2
         </em>
         ), splicing factors (eg,
         <em>
          SRSF2
         </em>
         ,
         <em>
          SF3B1
         </em>
         ,
         <em>
          ZRSF2
         </em>
         ), cytokine signaling (eg,
         <em>
          NRAS
         </em>
         ,
         <em>
          KRAS
         </em>
         ,
         <em>
          CBL
         </em>
         ,
         <em>
          JAK2
         </em>
         ), transcription factors (eg,
         <em>
          RUNX1
         </em>
         ), and mediators of DNA damage response (eg,
         <em>
          TP53
         </em>
         ,
         <em>
          PHF6
         </em>
         ) [
         <a href="#rid3">
          3-7
         </a>
         ]. Mutations in
         <em>
          SRSF2
         </em>
         and
         <em>
          ASXL1
         </em>
         are present in approximately 40 percent of cases of CMML [
         <a href="#rid5">
          5,7-9
         </a>
         ].
        </p>
        <p>
         The genetic determinants of the myeloproliferative and myelodysplastic features of CMML are uncertain. A large proportion of cases display hypersensitivity to GM-CSF in vitro, which likely contributes to the monocytic phenotype [
         <a href="#rid10">
          10-14
         </a>
         ]. Mutations in RAS pathway genes appear to skew the phenotype toward the myeloproliferative variant of CMML [
         <a href="#rid3">
          3,15
         </a>
         ]. As with myeloproliferative neoplasms, the bone marrow in CMML is characterized by an inflammatory cytokine microenvironment [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Importantly, certain mutations that are associated with myelodysplastic syndromes exclude the diagnosis of CMML, as described below. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H37528751">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of CMML is poorly defined, in part because CMML had previously been categorized as either a myeloproliferative neoplasm (MPN) or myelodysplastic neoplasms/syndromes (MDS).
        </p>
        <p>
         CMML occurs most commonly in older adults, with a median age at diagnosis of 65 to 75 years and a male:female ratio of 1.5 to 3.1 [
         <a href="#rid17">
          17-19
         </a>
         ]. A study that used centralized morphologic review of a well-defined population reported a prevalence of 1 to 2 cases per 100,000 population per year [
         <a href="#rid20">
          20
         </a>
         ]. Another study reported a similar incidence and also noted the highest incidence in patients &gt;80 years of age [
         <a href="#rid21">
          21
         </a>
         ]. The actual incidence may be higher because of the nonspecific clinical presentation, misclassification (as either MDS or MPN), and because a diagnostic bone marrow examination may not be performed in some older or frail patients [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         CMML is not known to be an inherited disorder. No environmental exposure has been definitively linked to CMML, but some cases occur in patients after treatment with chemotherapy or ionizing radiation. Such therapy-related CMML represents approximately one-tenth of all cases [
         <a href="#rid23">
          23-25
         </a>
         ]. In one study, secondary CMML (ie, CMML arising from antecedent MDS) accounted for approximately 6 percent of CMML [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H37528764">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical findings of CMML are nonspecific, but patients may present with myeloproliferative-type symptoms and/or findings related to cytopenias; other patients are asymptomatic at presentation.
        </p>
        <p>
         Clinically, CMML can be divided into dysplastic (white blood cell [WBC] count &lt;13,000/microL; 13 x 10
         <sup>
          9
         </sup>
         /L) versus proliferative (WBC &gt;13,000/microL) subtypes [
         <a href="#rid27">
          27-30
         </a>
         ]. Patients with proliferative-type CMML are more likely to have constitutional symptoms (eg, weight loss, fever, night sweats), whereas the dysplastic subtype is more often associated with consequences of cytopenias (eg, fatigue, infection, bleeding/bruising) [
         <a href="#rid17">
          17-19
         </a>
         ]. Individuals may have a combination of dysplastic and proliferative symptoms.
        </p>
        <p>
         Splenomegaly and hepatomegaly, which may present with early satiety or abdominal fullness, is noted in up to one-half of patients with proliferative-type CMML but is less common with dysplastic-type CMML [
         <a href="#rid17">
          17
         </a>
         ]. Nodular cutaneous leukemic infiltrates or gingival infiltration are seen occasionally, while central nervous system involvement or life-threatening hyperleukocytosis are rare [
         <a href="#rid31">
          31,32
         </a>
         ]. Renal insufficiency, especially in the proliferative subtype of CMML [
         <a href="#rid33">
          33
         </a>
         ], may be related to renal infiltration by monocytes and/or lysozyme secretion [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         Many patients are initially asymptomatic, such as when CMML is first suspected because a routine blood count revealed mild anemia, neutropenia, monocytosis, and/or thrombocytopenia. Other patients present with an antecedent autoimmune illness (eg, rheumatoid arthritis) or other inflammatory condition [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3129037578">
         <span class="h1">
          PATHOLOGIC FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H37530089">
         <span class="h2">
          Peripheral blood
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hallmark of CMML is peripheral blood clonal monocytosis; in addition, at least one-half of cases manifest an elevated total white blood cell (WBC) count at presentation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monocytes and blasts
         </strong>
         – CMML is associated with increased circulating monocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A defining feature of CMML is an absolute monocyte count (AMC) ≥500/microL (0.5 x
         <sup>
         </sup>
         10
         <sup>
          9
         </sup>
         /L) with monocytes accounting for ≥10 percent of peripheral blood WBCs [
         <a href="#rid2">
          2,38
         </a>
         ]. The AMC is usually 2000 to 5000/microL but can be &gt;80,000/microL in rare cases. It should be noted that the previous diagnostic threshold for AMC was ≥1000/microL [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Monocytes are generally mature with minimal morphologic atypia, but atypical monocytes with abnormalities of nuclear segmentation, unusually fine chromatin, or abnormal cytoplasmic granules can be present (
         <a class="graphic graphic_picture graphicRef85880" href="/z/d/graphic/85880.html" rel="external">
          picture 1
         </a>
         ). These atypical monocytes should be distinguished from promonocytes, which are considered blast equivalents in CMML. Immature cells, including monoblasts, promonocytes, and blasts may be present in the blood smear. Importantly, acute myeloid leukemia (AML) should be diagnosed if such immature forms account for ≥20 percent of leukocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As discussed separately, staging of CMML requires accurate quantitation of blasts. (See
         <a class="medical medical_review" href="/z/d/html/128330.html" rel="external">
          "Chronic myelomonocytic leukemia: Management and prognosis", section on 'Disease stage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutrophils
         </strong>
         – Neutrophilia contributes to leukocytosis in CMML, but neutrophil precursors (eg, promyelocytes, myelocytes) usually account for &lt;10 percent of leukocytes [
         <a href="#rid17">
          17,40-42
         </a>
         ]. It can be difficult to distinguish dysplastic monocytes from hypogranular neutrophils; in many cases, distinctive mononuclear cells with features intermediate between myelocytes and monocytes ("paramyeloid cells") are apparent. Neutrophil dysplasia (eg, hypersegmented or abnormally segmented nuclei or abnormal cytoplasmic granulation) is easily apparent in the dysplastic subtype of CMML but may be subtle in the proliferative subtype [
         <a href="#rid40">
          40,43
         </a>
         ]. The subtypes of CMML are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128330.html" rel="external">
          "Chronic myelomonocytic leukemia: Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Red blood cells and platelets
         </strong>
         – Mild normocytic or macrocytic anemia is common and platelet counts vary, but there is often moderate thrombocytopenia. Nucleated red blood cells and atypical, large platelets may be seen on the blood smear [
         <a href="#rid40">
          40,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eosinophils
         </strong>
         – In rare cases with ≥1500 eosinophils/microL, CMML must be distinguished from myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusions, as described below. (See
         <a class="local">
          'Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Cytochemical staining, flow cytometry, cytogenetics, and molecular features of blood cells are described below. (See
         <a class="local">
          'Bone marrow'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H37530095">
         <span class="h2">
          Bone marrow
         </span>
        </p>
        <p class="headingAnchor" id="H1755789162">
         <span class="h3">
          Microscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no pathognomonic morphologic feature of CMML, but bone marrow is generally hypercellular with dysplasia and it contains abundant mononuclear cells, granulocytes, and myeloid progenitors.
        </p>
        <p>
         Bone marrow is hypercellular in &gt;75 percent of cases, but some cases are normocellular or occasionally hypocellular [
         <a href="#rid19">
          19,45-47
         </a>
         ]. Bone marrow has &lt;20 percent blasts (including myeloblasts, monoblasts, and promonocytes); by definition, blast counts &gt;20 percent establish a diagnosis of AML. Mature monocytes should be excluded from the blast count, although the distinction between atypical monocytes and immature forms can be challenging when there is substantial dysplasia. (See
         <a class="local">
          'Peripheral blood'
         </a>
         above.)
        </p>
        <p>
         Monocytic and granulocytic cells are abundant, but these lineages may be difficult to distinguish by morphology alone [
         <a href="#rid42">
          42,45
         </a>
         ]. Bone marrow dysplasia resembles that of myelodysplastic neoplasms/syndromes (MDS), but dysplastic features in CMML can be subtle. Ring sideroblasts have also been reported in CMML, but the biologic and prognostic significance is unclear. Nodules of plasmacytoid dendritic cells that are clonally related to the CMML can be seen in the bone marrow in 20 percent of patients; this finding may be associated with adverse prognosis [
         <a href="#rid48">
          48
         </a>
         ]. Other dysplastic features of CMML cells are described above. (See
         <a class="local">
          'Peripheral blood'
         </a>
         above.)
        </p>
        <p>
         Megakaryocyte dysplasia is present in &gt;80 percent of the cases; in occasional cases, megakaryocytes are the only lineage that manifests overt dysplasia. Dysplastic forms may include micromegakaryocytes and small hypolobate forms [
         <a href="#rid39">
          39
         </a>
         ]. Clustering of megakaryocytes is usually not seen. Bone marrow fibrosis can be seen in CMML, but its significance is unclear.
        </p>
        <p class="headingAnchor" id="H2060429765">
         <span class="h3">
          Cytochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytochemical studies are valuable for characterizing CMML [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Monocytes are positive for alpha-naphthyl butyrate esterase or alpha-naphthyl acetate esterase (with fluoride inhibition), alone, or in combination with naphthol AS-D [
         <a href="#rid39">
          39
         </a>
         ]. Chloroacetate esterase (CAE) staining may be useful for distinguishing monocytes from granulocytic precursors.
        </p>
        <p class="headingAnchor" id="H3824914132">
         <span class="h3">
          Immunophenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunophenotyping can aid quantitation of monocytes and reveal antigenic abnormalities of monocytic forms, myeloid blasts, and maturing myelomonocytic cells. Multicolor flow cytometry is more sensitive than immunohistochemistry for characterizing the immunophenotype.
        </p>
        <p>
         The bulk of bone marrow cells in CMML express typical myelomonocytic antigens (CD33, CD13) and variably express CD14, CD68, and CD64 [
         <a href="#rid49">
          49-52
         </a>
         ]. In virtually all cases of CMML there is a relative increase in classical monocytes (defined by expression of CD14 and absence of CD16) in bone marrow and peripheral blood [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         As with their morphology, blood and bone marrow monocytes have aberrant immunophenotypes, with two or more aberrant features by flow cytometry [
         <a href="#rid53">
          53
         </a>
         ]. Decreased expression of CD14 may reflect immaturity of monocytes [
         <a href="#rid13">
          13
         </a>
         ]. Other atypical immunophenotypic features include overexpression of CD56; aberrant expression of CD2; and decreased expression of HLA-DR, CD13, CD11c, CD15, CD16, CD64, and CD36 [
         <a href="#rid13">
          13,53-55
         </a>
         ]. An increased fraction of CD34+ cells and/or an emerging population of blasts with an aberrant immunophenotype may suggest transformation to acute leukemia [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
         The most reliable immunohistochemical staining of tissue sections is for CD14, CD68R, and CD163 [
         <a href="#rid46">
          46,58
         </a>
         ]. Lysozyme staining can complement CAE cytochemistry to identify monocytic cells (which are lysozyme positive, but CAE negative); this contrasts with granulocytic precursors, which are positive for both.
        </p>
        <p class="headingAnchor" id="H1101066021">
         <span class="h3">
          Cytogenetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytogenetic abnormalities are identified in 20 to 40 percent of CMML cases, but no finding is specific to this disease [
         <a href="#rid3">
          3
         </a>
         ]. Cytogenetic features are used in several of the CMML prognostic systems. (See
         <a class="medical medical_review" href="/z/d/html/128330.html" rel="external">
          "Chronic myelomonocytic leukemia: Management and prognosis"
         </a>
         .)
        </p>
        <p>
         The most common recurrent cytogenetic abnormalities in CMML are gain of chromosome 8, loss of chromosome 7, del(7q), -Y, and complex karyotypes [
         <a href="#rid1">
          1,19,59-61
         </a>
         ]. A study of 414 patients with CMML reported a normal karyotype in 73 percent, 7 percent had trisomy 8, 4 percent had loss of chromosome Y, 3 percent had a complex karyotype, 1.5 percent had an abnormality of chromosome 7, and 10 percent had another aberration [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H37530101">
         <span class="h3">
          Molecular features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Somatic mutations are found in &gt;90 percent of patients with CMML [
         <a href="#rid2">
          2
         </a>
         ]. The most common mutations are
         <em>
          TET2
         </em>
         (58 percent),
         <em>
          SRSF2
         </em>
         (46 percent),
         <em>
          ASXL1
         </em>
         (40 percent),
         <em>
          RUNX1
         </em>
         (15 percent),
         <em>
          NRAS
         </em>
         (11 percent),
         <em>
          CBL
         </em>
         (10 percent), and others (&lt;10 percent) [
         <a href="#rid4">
          4,63
         </a>
         ]. Most cases have a mutation of either
         <em>
          TET2
         </em>
         ,
         <em>
          SRSF2
         </em>
         ,
         <em>
          SETBP1
         </em>
         , or
         <em>
          ASXL1
         </em>
         [
         <a href="#rid5">
          5,64,65
         </a>
         ]. Mutations of
         <em>
          NPM1
         </em>
         are uncommon (&lt;5 percent of cases). If an
         <em>
          NPM1
         </em>
         mutation is present, this may indicate AML with monocytic differentiation or CMML with a high probability of progressing to AML [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         As discussed below, when mutations are present at a variant allele frequency (VAF) &gt;10 percent, they can be used as a marker of clonality; this can establish a diagnosis of CMML even in the absence of dysplasia and with a lower absolute monocyte count (&gt;500/microL). (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         Somatic mutations are used in several CMML prognostic models. (See
         <a class="medical medical_review" href="/z/d/html/128330.html" rel="external">
          "Chronic myelomonocytic leukemia: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37528776">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation of a patient suspected to have CMML includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – The history should elicit symptoms related to cytopenias (eg, weakness or fatigue from anemia; recurrent infections from neutropenia; bleeding/bruising from thrombocytopenia), splenomegaly (eg, early satiety or weight loss), and constitutional symptoms. Prior treatment with chemotherapy, transfusion history, and prior monocytosis should be documented.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood counts/smear
         </strong>
         – A complete blood count (CBC) with differential count should be evaluated for monocytosis, cytopenias, and the percentage of blasts. The blood smear should be examined for dysplasia and blasts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow examination
         </strong>
         – Bone marrow should be examined for cellularity, percentage of monocytes and monoblasts, and evidence of dysplasia, as described above. (See
         <a class="local">
          'Microscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics/molecular evaluation
         </strong>
         – Karyotype and genetic profiling can be performed with conventional cytogenetics and/or fluorescence in situ hybridization (FISH) of blood or bone marrow. A myeloid gene panel or other method for mutation analysis can document clonality and identify mutated genes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cytogenetics must exclude t(9;22) chromosomal translocation (ie, Philadelphia chromosome) and/or
         <em>
          BCR::ABL1
         </em>
         rearrangement and abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia (eg,
         <em>
          PDGFRA-
         </em>
         or
         <em>
          PDGFRB-
         </em>
         rearrangement,
         <em>
          FGFR1-
         </em>
         rearrangement,
         <em>
         </em>
         or
         <em>
          PCM1::JAK2
         </em>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H37528782">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMML should be considered in an adult with persistent, unexplained monocytosis, cytopenias, and/or proliferative symptoms.
        </p>
        <p>
         Diagnostic criteria for CMML are evolving and current diagnostic systems differ subtly [
         <a href="#rid2">
          2,38
         </a>
         ]. Note that, compared with the previous diagnostic threshold for monocytes (≥1000/microL), contemporary diagnostic criteria apply a lower threshold when there is evidence of clonality (described below).
        </p>
        <p class="headingAnchor" id="H164364009">
         <span class="h2">
          International Consensus Classification (ICC) criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICC criteria for diagnosis of CMML [
         <a href="#rid2">
          2
         </a>
         ] are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monocytosis
         </strong>
         – Absolute monocyte count (AMC) &gt;500/microL (0.5 x 10
         <sup>
          9
         </sup>
         /L) with monocytes accounting for &gt;10 percent of the white blood cell (WBC) differential count.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytopenia
         </strong>
         – At least one cytopenia:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anemia
         </strong>
         – Hemoglobin &lt;13 g/dL in males, &lt;12 g/dL in females
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neutropenia
         </strong>
         – Absolute neutrophil count (ANC) &lt;1.8 x 10
         <sup>
          9
         </sup>
         /L
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thrombocytopenia
         </strong>
         – Platelets &lt;150 x 10
         <sup>
          9
         </sup>
         /L
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with early stage CMML may show only borderline or no cytopenia; such cases require marrow morphology, flow cytometry, and molecular data to support a diagnosis of CMML [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blasts
         </strong>
         – Blasts (myeloblasts, monoblasts, and promonocytes) constitute &lt;20 percent of cells in blood and marrow.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clonality
         </strong>
         – Abnormal cytogenetics and/or ≥1 myeloid neoplasm-associated mutation (with ≥10 percent variant allele frequency [VAF]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In cases without evidence of clonality, CMML can be diagnosed by AMC &gt;1.0 x 10
         <sup>
          9
         </sup>
         /L and &gt;10 percent of WBC
         <strong>
          plus
         </strong>
         at least one of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased blasts plus promonocytes (≥5 percent in marrow or &gt;2 percent in blood)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Morphologic dysplasia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abnormal immunophenotype, consistent with CMML
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow
         </strong>
         – Hypercellular marrow, often with increased monocytes, that lacks diagnostic features of acute myeloid leukemia, MPNs, or other conditions associated with monocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exclude other MPNs
         </strong>
         – No
         <em>
          BCR::ABL1
         </em>
         or abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (ie,
         <em>
          PDGFRA-
         </em>
         or
         <em>
          PDGFRB-
         </em>
         rearrangement,
         <em>
          FGFR1-
         </em>
         rearrangement,
         <em>
         </em>
         or
         <em>
          PCM1::JAK2
         </em>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H791635037">
         <span class="h2">
          World Health Organization 5th edition (WHO5) criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         WHO5 criteria are [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis requires:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prerequisite criteria (below) must be met in all cases:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If monocytosis is ≥1 × 10
         <sup>
          9
         </sup>
         /L: One or more supporting criteria (below) must be met.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If monocytosis is ≥0.5 and &lt;1 × 10
         <sup>
          9
         </sup>
         /L: Supporting criteria 1 and 2 must be met.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          WHO5
         </strong>
         <strong>
          prerequisite criteria
         </strong>
         (all are required):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Monocytosis
         </strong>
         – AMC ≥500/microL (0.5 x 10
         <sup>
          9
         </sup>
         /L) and relative ≥10 percent monocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Blasts
         </strong>
         – Blasts (myeloblasts, monoblasts, and promonocytes) constitute &lt;20 percent of cells in blood and marrow.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Exclude other MPNs
         </strong>
         – Not meeting diagnostic criteria for chronic myeloid leukemia (CML) or other MPNs.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Exclude myeloid/lymphoid neoplasms with tyrosine kinase fusions
         </strong>
         – Not meeting diagnostic criteria of myeloid/lymphoid neoplasms with tyrosine kinase fusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          WHO5 Supporting criteria
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         1) Dysplasia (≥10 percent morphologic dysplasia of cells of a lineage) involving ≥1 myeloid lineages
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         2) Acquired clonal cytogenetic or molecular abnormality
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         3) Abnormal partitioning of peripheral blood monocyte subsets (ie, detection of increased classical monocytes [&gt;94 percent] in the absence of known active autoimmune diseases and/or systemic inflammatory syndromes)
        </p>
        <p>
        </p>
        <p>
         Note that the ICC and WHO5 diagnostic criteria for CMML differ subtly. The ICC includes a category called clonal monocytosis of undetermined significance (CMUS) [
         <a href="#rid2">
          2
         </a>
         ] that the WHO5 would describe as CMML [
         <a href="#rid38">
          38
         </a>
         ]. CMUS is defined by:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AMC ≥0.5 x 10
         <sup>
          9
         </sup>
         /L with monocytes ≥10 percent of WBCs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No MDS-defining cytopenias
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A myeloid-driver somatic mutation with VAF ≥2 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No bone marrow morphologic findings of CMML [
         <a href="#rid2">
          2
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Both ICC and WHO5 recognize dysplastic-type and proliferative-type CMML as distinct subtypes of CMML. All cases should be subclassified according to both the percentage of blasts in blood and bone marrow and the total WBC count, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/128330.html" rel="external">
          "Chronic myelomonocytic leukemia: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37528788">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMML must be distinguished from other disorders associated with monocytosis and/or dysplasia, including reactive disorders, chronic myeloid leukemia (CML), other myeloproliferative neoplasms (MPN), and myelodysplastic neoplasms/syndromes (MDS).
        </p>
        <p class="headingAnchor" id="H704912580">
         <span class="h2">
          Distinguishing CMML from other monocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMML can be difficult to distinguish from other causes of monocytosis. While there are no pathognomonic cytogenetic or molecular abnormalities associated with CMML, certain findings can support or exclude the diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – One study suggested that when CD14+, CD16-negative monocytes account for &gt;94 percent of total monocytes on flow cytometry, reactive monocytosis and most other hematologic malignancies can be excluded; using this criterion, the sensitivity and specificity for CMML were 94 and 92 percent, respectively [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – Somatic mutations are detectable in &gt;90 percent of cases of CMML [
         <a href="#rid67">
          67
         </a>
         ]. While mutations of
         <em>
          TET2
         </em>
         ,
         <em>
          SRSF2
         </em>
         ,
         <em>
          ASXL1
         </em>
         , or
         <em>
          SETBP1
         </em>
         are supportive of a diagnosis of CMML, they are not sufficient to establish the diagnosis. A variant allele frequency (VAF) &gt;10 percent may be helpful in distinguishing CMML from clonal hematopoiesis of indeterminate potential (CHIP) or related disorders. (See
         <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">
          "Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Importantly, the following genetic alterations exclude a diagnosis of CMML:
         <em>
          BCR::ABL1, PDGFRA-
         </em>
         or
         <em>
          PDGFRB-
         </em>
         rearrangement
         <em>
          s, FGFR1-
         </em>
         rearrangmen
         <em>
          t, PCM1::JAK2
         </em>
         . (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior disorders
         </strong>
         – A prior history of an MPN excludes the diagnosis of CMML. The presence of mutations commonly seen in MPNs (
         <em>
          JAK2
         </em>
         ,
         <em>
          CALR
         </em>
         , or
         <em>
          MPL
         </em>
         ) favors a diagnosis of an MPN with associated monocytosis, rather than CMML.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4240417982">
         <span class="h2">
          Reactive monocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monocytosis, with or without associated neutrophilia, is a relatively nonspecific finding and reactive causes of monocytosis (ie, non-clonal monocytes) are often prominent in the differential diagnosis of CMML.
        </p>
        <p>
         Conditions that cause monocytosis include pregnancy, asplenia, corticosteroids, myeloid growth factors, and inflammatory or autoimmune conditions (eg, sarcoidosis, inflammatory bowel disease). Reactive monocytosis can be associated with Hodgkin lymphoma (ie, the monocytes are not part of the malignant clone). Infections that have been associated with monocytosis include brucellosis, varicella-zoster, bacterial endocarditis, tuberculosis, malaria, typhoid fever, syphilis, and trypanosomiasis.
        </p>
        <p>
         With extreme leukocytosis associated with a reactive cause (eg, severe infection, myeloid growth factors), even though the absolute monocyte count can be &gt;1000/microL, monocytes account for only a small fraction of the total white blood cell (WBC) count. In contrast, despite a relative increase in monocytes, many cases of CMML do not have an elevated total WBC count. Evaluation of neutrophilia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37528794">
         <span class="h2">
          Myelodysplastic syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dysplasia is present in both CMML and MDS. Dysplasia in CMML is generally more subtle and is typically seen in &lt;10 percent of mononuclear cells, but higher degrees of dysplasia are compatible with the diagnosis. Although MDS may exhibit modest or fluctuating monocytosis, CMML has persistent peripheral blood monocytosis (ie, &gt;500 monocytes/microL) and often manifests other proliferative features such as splenomegaly, leukocytosis, and constitutional symptoms (
         <a class="graphic graphic_picture graphicRef85880" href="/z/d/graphic/85880.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
         The mutations associated with CMML do not distinguish it from MDS, and vice versa. However,
         <em>
          SETBP1
         </em>
         and/or
         <em>
          SRSF2
         </em>
         mutations are more common in overlap disorders than in MDS and their presence may favor a diagnosis of CMML or another MDS/MPN.
        </p>
        <p>
         Other diagnostic features of MDS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2547550396">
         <span class="h2">
          Myeloproliferative neoplasms
         </span>
        </p>
        <p class="headingAnchor" id="H37528800">
         <span class="h3">
          Chronic myeloid leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both CML and CMML may manifest findings related to proliferative features (eg, splenomegaly, B symptoms), but the presence of the
         <em>
          BCR::ABL1
         </em>
         rearrangement and/or t(9;22), the Philadelphia chromosome, confirms the diagnosis of CML and excludes CMML. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3096737046">
         <span class="h3">
          Other MPNs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic neutrophilic leukemia (CNL) may present with proliferative features, including constitutional symptoms, splenomegaly, and leukocytosis; bone marrow is generally hypercellular in PV, the cellular phase of PMF, and CNL. These MPNs typically exhibit polycythemia and/or thrombocytosis and generally lack the persistent absolute monocytosis and dysplastic features of CMML. Although
         <em>
          JAK2
         </em>
         V617F can be associated with both MPNs and CMML, the other characteristic mutations associated with MPNs (eg,
         <em>
          MPL, CALR, CSF3R
         </em>
         ) are not seen with CMML.
        </p>
        <p>
         Details of the characteristic features and diagnosis of these MPNs are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">
          "Overview of the myeloproliferative neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1058672852">
         <span class="h2">
          Myeloproliferative/myelodysplastic syndromes
         </span>
        </p>
        <p class="headingAnchor" id="H1943719411">
         <span class="h3">
          Juvenile myelomonocytic leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Juvenile myelomonocytic leukemia (JMML) is a rare disorder of infancy and early childhood characterized by hepatosplenomegaly, lymphadenopathy, pallor, fever, and skin rash (
         <a class="graphic graphic_table graphicRef110232" href="/z/d/graphic/110232.html" rel="external">
          table 1
         </a>
         ). Patients with JMML demonstrate clonal overproduction of maturing myeloid cells. Progression to acute leukemia is rare. The karyotype in JMML is often normal but sometimes shows monosomy 7. Although JMML and CMML share certain clinical and pathologic features, the ages of affected patients are clearly distinct. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia", section on 'Juvenile myelomonocytic leukemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37530107">
         <span class="h3">
          Atypical CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical CML (aCML) is a
         <em>
          BCR::ABL1
         </em>
         -negative is an uncommon MDS/MPN syndrome that, like CMML, is characterized by both dysplasia and myeloid proliferation. The entity is uncommon, but it can cause a considerable diagnostic challenge. Monocytosis is common in aCML but, by definition, monocytes are &lt;10 percent of the blood differential count. aCML is characterized by profound dysgranulopoiesis, absence of the
         <em>
          BCR::ABL1
         </em>
         fusion gene, and neutrophilia (
         <a class="graphic graphic_table graphicRef110230" href="/z/d/graphic/110230.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia", section on '"Atypical CML"'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2973691358">
         <span class="h3">
          MDS/MPN unclassifiable
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both CMML and MDS/MPN, unclassifiable (MDS/MPN-U) have clinical and pathologic features that overlap MPNs and MDS. MDS/MPN-U includes cases that display MDS and MPN features but cannot be classified as aCML, CMML, or JMML. By definition, cases of MDS/MPN-U cannot have peripheral monocytes &gt;1000/microL that corresponds to &gt;10 percent of the differential count.
        </p>
        <p class="headingAnchor" id="H37530113">
         <span class="h2">
          Systemic mastocytosis with associated hematologic neoplasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is manifested by systemic mastocytosis and a second hematologic neoplasm [
         <a href="#rid39">
          39
         </a>
         ]. The most common associated hematologic neoplasm with mastocytosis is CMML [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         SM-AHN is characterized by mastocytosis-like symptoms (eg, diarrhea, pruritus, intermittent hypotension, nausea, ocular symptoms, anaphylaxis) and has a particularly aggressive natural history. Abnormal mast cell infiltrates in the bone marrow biopsy are often the sentinel finding. The activating mutation,
         <em>
          KIT
         </em>
         D816V, is present in most cases of SM-AHN (in both the mastocytes and the associated hematologic neoplasm cells).
        </p>
        <p>
         Other aspects of the diagnosis of SM-AHN are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">
          "Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3791463037">
         <span class="h2">
          Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myeloid and lymphoid variants of eosinophilia include MPNs with certain molecular abnormalities, including those involving
         <em>
          PDGFRA, PDGFRB, FGFR1
         </em>
         ,
         <em>
          PCM1::JAK2
         </em>
         , and other rare rearrangements; the presence of one of these molecular abnormalities excludes the diagnosis of CMML.
        </p>
        <p>
         Details of these eosinophilic conditions are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">
          "Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Myeloproliferative HES variants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2399091041">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116776.html" rel="external">
          "Society guideline links: Myeloproliferative neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37528879">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy with clinical and pathologic features of both myeloproliferative neoplasms (MPN) and myelodysplastic neoplasms/syndromes (MDS). CMML is characterized by peripheral blood monocytosis, cytopenia, and clonality, often accompanied by splenomegaly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Cytogenetic and molecular abnormalities are common in CMML, but none is diagnostic. Mutations in epigenetic modifiers or splicing factors are found in most cases. Genetic alterations appear to converge on a phenotype skewed towards hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and monocytopoiesis. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presentation
         </strong>
         – Clinical findings are nonspecific, but patients can present with proliferative-type symptoms (eg, constitutional symptoms, splenomegaly) and/or findings related to cytopenias. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathology
         </strong>
         – Features include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Blood
         </strong>
         – Monocytosis (absolute monocyte count [AMC] ≥500/microL [≥0.5 x 10
         <sup>
          9
         </sup>
         /L]) is the hallmark of CMML; monocytes account for ≥10 percent of leukocytes. (See
         <a class="local">
          'Peripheral blood'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Monocytes are generally mature, but they can exhibit dysplasia with aberrant nuclear segmentation, disordered chromatin, or abnormal cytoplasmic granulation (
         <a class="graphic graphic_picture graphicRef85880" href="/z/d/graphic/85880.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bone marrow
         </strong>
         – Bone marrow is generally hypercellular, but it has &lt;20 percent blasts; cytochemical, immunophenotypic, cytogenetic, and molecular findings are described above. (See
         <a class="local">
          'Bone marrow'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – CMML should be considered in an adult with persistent, unexplained monocytosis, cytopenias, and/or proliferative symptoms. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Diagnostic criteria are evolving; criteria developed by the International Consensus Classification [
         <a href="#rid2">
          2
         </a>
         ] are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monocytosis
         </strong>
         – AMC &gt;500/microL with monocytes accounting for &gt;10 percent of the white blood cell (WBC) differential count
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cytopenia
         </strong>
         – At least one affected lineage
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Blasts
         </strong>
         – Blasts (myeloblasts, monoblasts, and promonocytes) constitute &lt;20 percent of cells in blood and marrow
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clonality
         </strong>
         – Abnormal cytogenetics and/or ≥1 MPN-associated mutation (with ≥10 percent allele frequency)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bone marrow
         </strong>
         – Hypercellular marrow, often with increased monocytes, that lacks diagnostic features of acute myeloid leukemia, MPNs, or other conditions associated with monocytosis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Exclude other MPNs
         </strong>
         – No
         <em>
          BCR::ABL1
         </em>
         or abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (ie,
         <em>
          PDGFRA-
         </em>
         or
         <em>
          PDGFRB-
         </em>
         rearrangement,
         <em>
          FGFR1-
         </em>
         rearrangement,
         <em>
         </em>
         or
         <em>
          PCM1::JAK2
         </em>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         – All cases should be subclassified according to the WBC count and percentage of blasts in peripheral blood and bone marrow, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/128330.html" rel="external">
          "Chronic myelomonocytic leukemia: Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – CMML must be distinguished from other conditions associated with monocytosis and/or dysplasia, including reactive causes, MPNs, and MDS. Molecular rearrangements that exclude CMML are described above. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H329495339">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge David P Steensma, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia 2013; 27:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31:2428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120:3080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood 2015; 125:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elena C, Gallì A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 2016; 128:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood 2014; 124:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padron E, Painter JS, Kunigal S, et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 2013; 121:5068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramshaw HS, Bardy PG, Lee MA, Lopez AF. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol 2002; 30:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotecha N, Flores NJ, Irish JM, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008; 14:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 2015; 125:3618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talati C, Zhang L, Shaheen G, et al. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood 2017; 129:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr RM, Vorobyev D, Lasho T, et al. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun 2021; 12:2901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niyongere S, Lucas N, Zhou JM, et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia 2019; 33:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Germing U, Gattermann N, Minning H, et al. Problems in the classification of CMML--dysplastic versus proliferative type. Leuk Res 1998; 22:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solal-Celigny P, Desaint B, Herrera A, et al. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood 1984; 63:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storniolo AM, Moloney WC, Rosenthal DS, et al. Chronic myelomonocytic leukemia. Leukemia 1990; 4:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res 2011; 35:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinmohamed AG, van Norden Y, Visser O, et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res 2015; 39:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McQuilten ZK, Wood EM, Polizzotto MN, et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. Cancer 2014; 120:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi K, Pemmaraju N, Strati P, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 2013; 122:2807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subari S, Patnaik M, Alfakara D, et al. Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. Clin Lymphoma Myeloma Leuk 2015; 15:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patnaik MM, Vallapureddy R, Yalniz FF, et al. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol 2018; 93:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padron E, Yoder S, Kunigal S, et al. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 2014; 123:3675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuler E, Schroeder M, Neukirchen J, et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res 2014; 38:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013; 121:3005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cervera N, Itzykson R, Coppin E, et al. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. Am J Hematol 2014; 89:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricci C, Fermo E, Corti S, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010; 16:2246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aul C, Gattermann N, Germing U, et al. Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia. Leuk Res 1997; 21:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew RA, Bennett JM, Liu JJ, et al. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res 2012; 36:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter AM, Al Ali N, Mai A, et al. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leuk Res 2021; 109:106640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel AB, Miles RR, Deininger MW. Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep 2019; 7:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asano M, Hase H, Naruse Y, et al. A rare cause of acute kidney injury with chronic myelomonocytic leukemia. CEN Case Rep 2021; 10:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zahid MF, Barraco D, Lasho TL, et al. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 2017; 58:1488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peker D, Padron E, Bennett JM, et al. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol 2015; 133:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Français de Cytogénétique Hématologique. Blood 1991; 78:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994; 87:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 1996; 33:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Germing U, Strupp C, Giagounidis A, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res 2012; 36:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaux JL, Martiat P. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 1993; 9:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orazi A, Chiu R, O'Malley DP, et al. Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology. Mod Pathol 2006; 19:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schemenau J, Baldus S, Anlauf M, et al. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. Eur J Haematol 2015; 95:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas N, Duchmann M, Rameau P, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 2019; 33:2466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manaloor EJ, Neiman RS, Heilman DK, et al. Immunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens. Comparison with flow cytometry. Am J Clin Pathol 2000; 113:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kern W, Bacher U, Haferlach C, et al. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma 2011; 52:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen Q, Ouyang J, Tang G, et al. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol 2015; 95:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodlock TJ, Seshi B, Sham RL, et al. Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia. Leuk Res 1994; 18:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu Y, McKenna RW, Karandikar NJ, et al. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 2005; 124:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matarraz S, Almeida J, Flores-Montero J, et al. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. Cytometry B Clin Cytom 2017; 92:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sojitra P, Gandhi P, Fitting P, et al. Chronic myelomonocytic leukemia monocytes uniformly display a population of monocytes with CD11c underexpression. Am J Clin Pathol 2013; 140:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anneroth G, Hall G, Rydén H, Zetterqvist L. The effect of low-energy infra-red laser radiation on wound healing in rats. Br J Oral Maxillofac Surg 1988; 26:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunphy CH, Orton SO, Mantell J. Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and of flow cytometric immunophenotyping to the evaluation of absolute monocytoses. Am J Clin Pathol 2004; 122:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qubaja M, Marmey B, Le Tourneau A, et al. The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukemia. Virchows Arch 2009; 454:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang G, Zhang L, Fu B, et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 2014; 89:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tefferi A, Hoagland HC, Therneau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989; 64:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patnaik MM, Wassie EA, Padron E, et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J 2015; 5:e270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 2013; 98:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mughal TI, Cross NC, Padron E, et al. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica 2015; 100:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 2014; 28:2206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federmann B, Abele M, Rosero Cuesta DS, et al. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. Hum Pathol 2014; 45:2471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng J, Zuo Z, Fu B, et al. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol 2016; 96:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cargo C, Cullen M, Taylor J, et al. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood 2019; 133:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SA, Hutchinson L, Tang G, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013; 88:219.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 96031 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21109693" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cytogenetic risk stratification in chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23558522" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : An evolutionary perspective on chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23690417" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognostic score including gene mutations in chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22919025" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25343957" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27385790" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21909114" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Frequent pathway mutations of splicing machinery in myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24970933" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23632888" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384142" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18835035" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25852055" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28159734" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34006870" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30026572" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9766745" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Problems in the classification of CMML--dysplastic versus proliferative type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6582939" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2232890" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21708407" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25533930" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24643720" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23896412" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26189785" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29023992" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24904105" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25444076" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23372164" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24595958" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20371679" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9111170" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21782240" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34144312" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31183108" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lysozyme nephropathy in chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33403618" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A rare cause of acute kidney injury with chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27739921" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25413011" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2070054" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Français de Cytogénétique Hématologique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11806985" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7986717" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8722681" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Morphology and classification of the myelodysplastic syndromes and their pathologic variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22421409" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8477199" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17041567" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25600827" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30894665" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10874882" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Immunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens. Comparison with flow cytometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21219126" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25354960" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7511190" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16203279" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26282340" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24124148" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Chronic myelomonocytic leukemia monocytes uniformly display a population of monocytes with CD11c underexpression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3422818" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The effect of low-energy infra-red laser radiation on wound healing in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15539379" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and of flow cytometric immunophenotyping to the evaluation of absolute monocytoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19242719" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24782398" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2593715" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Chronic myelomonocytic leukemia: natural history and prognostic determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25555161" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23065521" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26341525" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24695057" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25305095" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25809997" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30606702" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440662" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
